Get the Stockscreener App
0.9936
3.53%
-0.0364
Ocugen Inc stock is traded at $0.9936, with a volume of 4.43M.
It is down -3.53% in the last 24 hours and up +7.52% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.03
Open:
$1
24h Volume:
4.43M
Relative Volume:
0.82
Market Cap:
$290.16M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-3.68
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-8.84%
1M Performance:
+7.52%
6M Performance:
+36.60%
1Y Performance:
-23.57%
1-Day Range:
$0.9425
$1.02
1-Week Range:
$0.9425
$1.11
52-Week Range:
$0.515
$1.40
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9936 | 300.79M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen, Inc. (NASDAQ:OCGN) Q2 2025 Earnings Call Transcript - Insider Monkey
Ocugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen Inc’s Earnings Call: Progress Amid Financial Challenges - MSN
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Is Ocugen Inc. stock overvalued or undervaluedWealth Building Target Finder For Every Investor - jammulinksnews.com
Ocugen: Q2 Earnings Snapshot - Norwalk Hour
Is it the right time to buy Ocugen Inc. stockBest Dividend Picks For 2025 - jammulinksnews.com
Ocugen Provides Business Update with Second Quarter 2025 Financial Results - GlobeNewswire
Ocugen's Strategic Path to 2026 BLA Filings and Global Gene Therapy Leadership - AInvest
Ocugen's Q2 2025 Earnings Call: Unpacking Contradictions in Trial Timelines, Manufacturing, and Strategic Direction - AInvest
Is Ocugen Inc. a growth stock or a value stockFree Stock Growth Plan For Smart Trading - jammulinksnews.com
Ocugen’s Revenue Surprised And Analysts Still See Room To Grow - Finimize
Ocugen Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Ocugen Provides Business Update with Second Quarter 2025 Financi - GuruFocus
Ocugen Provides Business Update with Second Quarter 2025 Financial Results | OCGN Stock News - GuruFocus
Ocugen: A High-Potential Biotech Play with Near-Term Catalysts and a Path to Profitability - AInvest
What makes Ocugen Inc. stock price move sharplyEntry Signal Guidance That Work - jammulinksnews.com
What is Ocugen Inc. company’s growth strategyAI Powered Tips With High Returns - jammulinksnews.com
Ocugen Wins Dismissal of Securities Lawsuit - TipRanks
Live Chart Scan Detects Wedge Pattern in Ocugen Inc.Verified Signal From Chart Patterns Detected - metal.it
Ocugen Defeats Investor Fraud Lawsuit Over Accounting Issues (1) - Bloomberg Law News
Ocugen Beats Investor Suit Over Financial Controls - Law360
Ocugen regains Nasdaq compliance after meeting minimum bid price requirement - Investing.com Nigeria
Ocugen regains Nasdaq compliance after meeting minimum bid price requirement By Investing.com - Investing.com South Africa
What are analysts’ price targets for Ocugen Inc. in the next 12 monthsAchieve consistent profits with expert strategies - jammulinksnews.com
What are Ocugen Inc. company’s key revenue driversAdvanced Screener Recommendation For 2025 - jammulinksnews.com
Published on: 2025-07-28 17:25:27 - metal.it
What catalysts could drive Ocugen Inc. stock higher in 2025Capitalize on stocks with high profit margins - jammulinksnews.com
Should I hold or sell Ocugen Inc. stock in 2025AI Powered Tips With High Returns - jammulinksnews.com
What markets is GWH.WS expanding into Is Ocugen Inc. stock a good long term investment optionHarness the power of proven investment plans - jammulinksnews.com
When is Ocugen Inc. stock expected to show significant growthAdvanced Screener Ideas For Fast Growth - jammulinksnews.com
How many analysts rate Ocugen Inc. as a “Buy”Get alerts on high-potential stock breakouts - jammulinksnews.com
Ocugen Announces Q2 2025 Financial Results Call and Business Update - MSN
How does Ocugen Inc. generate profit in a changing economyExceptional trading results - jammulinksnews.com
Ocugen Strengthens Leadership and Advisory Board as It Targets Three Biologics Filings in Three Years - MSN
How volatile is Ocugen Inc. stock compared to the marketDouble-digit growth - jammulinksnews.com
What are the latest earnings results for Ocugen Inc.Unlock powerful insights from market experts - jammulinksnews.com
Ocugen Inc. Stock Analysis and ForecastAccelerated financial growth - PrintWeekIndia
CGTLive®’s Weekly Rewind – July 25, 2025 - CGTLive®
What risks could impact Ocugen Inc. stock performanceRapidly growing investment returns - jammulinksnews.com
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):